https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-702014-05-16 00:00:002019-02-15 08:39:38Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / J Immunother Cancer 2014;2:10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / J Immunother Cancer 2014;2:102014-05-13 00:00:002019-02-15 08:46:23Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-642014-05-13 00:00:002021-11-15 13:30:25Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-07 / J Ovarian Res 2014 May;7:48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-07 / J Ovarian Res 2014 May;7:482014-05-07 00:00:002019-02-15 08:52:06The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-112014-05-02 00:00:002021-11-15 13:30:54Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-01 / Cytotherapy 2014 Jul;16(7):934-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-01 / Cytotherapy 2014 Jul;16(7):934-452014-05-01 00:00:002014-05-01 00:00:00Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-01 / Future Oncol 2014 May;10(6):911-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-01 / Future Oncol 2014 May;10(6):911-52014-05-01 00:00:002019-02-15 08:46:22Immunotherapy for high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-29 / Cancer Immunol. Immunother. 2014 Aug;63(8):797-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-29 / Cancer Immunol. Immunother. 2014 Aug;63(8):797-8062014-04-29 00:00:002019-02-15 08:52:30Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-14 / World J. Gastroenterol. 2014 Apr;20(14):3738-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-14 / World J. Gastroenterol. 2014 Apr;20(14):3738-502014-04-14 00:00:002019-02-15 08:39:39Colorectal cancer and immunity: what we know and perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-10 / Cell 2014 Apr;157(2):516-516.e1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-10 / Cell 2014 Apr;157(2):516-516.e12014-04-10 00:00:002019-02-15 08:39:41SnapShot: cancer vaccines
